Related Experiment Videos
[Diovan efficacy and tolerance in mild and moderate hypertension]
Insights
Diovan (valsartan), an angiotensin-II antagonist, effectively lowers blood pressure in patients with mild to moderate hypertension. This study found it safe and well-tolerated over an 8-week treatment period.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Hypertension is a significant global health concern.
- Angiotensin-II antagonists represent a key therapeutic class for managing blood pressure.
Purpose of the Study:
- To evaluate the clinical effectiveness of Diovan (valsartan) in patients with mild to moderate hypertension.
- To assess the safety and tolerance profile of Diovan (valsartan) in this patient group.
Main Methods:
- A trial involving 20 patients (mild to moderate hypertension) was conducted over 8 weeks.
- Patients received Diovan (valsartan) at 80 mg/day, with a potential increase to 160 mg/day if needed.
- Clinical effectiveness was measured by changes in systolic and diastolic blood pressure.
Main Results:
- A significant reduction in both systolic and diastolic blood pressure was observed within 2 weeks.
- The blood pressure-lowering effect was enhanced by week 8.
- 90% of patients achieved a diastolic blood pressure of 90 mm Hg or a 10% reduction.
Conclusions:
- Diovan (valsartan) demonstrated significant efficacy in treating mild to moderate hypertension.
- The medication was well-tolerated, with no adverse metabolic changes reported.
Aim:
To study clinical effectiveness and tolerance of diovan, a new angiotensin-II antagonist, in patients with mild and moderate blood hypertension (BH).
Materials And Methods:
The trial included 20 patients (13 males and 7 females) aged 35-60 years with mild and moderate BH. All the patients received diovan (valsartan) for 8 weeks in a dose 80 mg/day. If the hypotensive effect was inadequate, the dose was increased to 160 mg/day.
Results:
2-week treatment with diovan brought a significant fall of both systolic and diastolic blood pressure. In 8 weeks the hypotensive effect enhanced. Lowering of diastolic BP to 90 mm Hg or at least by 10% was achieved in 90% of the patients. Tolerance was good, unfavorable metabolic shifts were absent.
Conclusion:
Diovan proved to be effective and safe in therapy of patients with mild and moderate BH.